The third part summarizes studies in GT-KO mice that demonstrate the efficacy of anti-Gal/α-gal epitope interaction in mediating α-gal therapies in various disciplines, including the amplification of immunogenicity of inactivated whole virus vaccines, in situ conversion of tumors into vaccines that elicit a protective immune response against autologous tumor antigens, and acceleration of wound healing and prevention of scar formation in skin and myocardial injuries. This evidence concerns the gene GAL and neoplasm.